At the close of July 2016, a monthly increase of 11.09 % was observed, reaching 264,034 million bolivars (US$353.5 million).

This result makes Bancamiga the bank with the highest relative monthly growth among large banks and second year-over-year, with a growth of 266.45 %. Its performance was so outstanding that it significantly surpassed that of the Venezuelan Banking System (SBV), which decreased by 2.82 %.

Bancamiga’s market share increased by 1.11 percentage points within the private banking sector and by 0.68 percentage points within the Venezuelan Banking System (SBV) on a monthly basis.

Regarding foreign currency deposits, it climbed one position to fourth place in public deposits within the private banking sector, with an absorption rate of 11.01 % and 7.99 % of the Venezuelan banking system, consolidating its position as a benchmark in the segment.

In July 2016, Bancamiga closed with 180.39 billion bolivars (US$242 million), positioning itself as the third bank with the highest proportion of foreign currency deposits in the system, at 68.32 %. On a monthly basis, it absorbed 2.87 percentage points from the private banking sector and 2.13 percentage points from the SBV.

These results reflect Bancamiga’s commitment to offering innovative products and services, along with close and personalized attention, allowing them to meet their clients’ expectations.

Total assets increased by 15.27 %. The institution with the highest percentage growth among large banks

July’s results regarding total assets strengthened Bancamiga’s position as the sixth largest bank in the country in terms of asset volume.

At the end of that month, total assets reached 411,017 million bolivars, equivalent to 520 million dollars, representing a monthly increase of 15.27 % and an annual increase of 220.58 %, respectively. Bancamiga positioned itself as the institution with the highest percentage growth among large banks during this period.

The average monthly growth of total assets was 18.53 %, surpassing that of the financial system (16.72 %).

As it approaches its 20th anniversary, Bancamiga reaffirms with these results its unwavering commitment to being the modern, approachable, and solid bank its customers deserve.

Based on information from Bancamiga Banco Universal’s institutional press release and other national media outlets

Follow our news on Google! For current, interesting, and accurate information, click here to see all the content on Bitfinance.news. You can also find us on X/Twitter and Instagram

La entrada Bancamiga consolidates growth driven by foreign currency deposits apareció primero en Bitfinance.

Stéphane Bancel, CEO of Moderna, reveals that the company’s experimental melanoma vaccine could reach the market in just two years, marking a historic milestone in the fight against the most serious form of skin cancer.

With 325,000 new cases and 57,000 deaths worldwide by 2020, melanoma is a global health concern.

Bancel points out that “in some countries, the product could be launched with accelerated approval by 2025″, highlighting the potential positive impact of this new therapeutic vaccine.

Unlike conventional vaccines, these therapeutic vaccines not only prevent, but also treat diseases by training the immune system against the invading agent.

Bancel describes therapeutic vaccines as “immunotherapy 2.0” and highlights the support for Moderna’s projects with the recent results of clinical trials, which reveal significant improvements in the chances of survival thanks to the vaccine.

The technology behind this breakthrough is messenger RNA (mRNA), previously successful in treating severe forms of Covid-19.

In a study of 157 people with advanced melanoma, Moderna’s vaccine, combined with Merck’s immunotherapy drug Keytruda, reduced the risk of recurrence or death by 49% over three years, compared with Keytruda alone.

Earlier results in 2022 had already shown a 44 % risk reduction over two years. Bancel highlights the growing difference in survival over time, stressing that the rate of side effects has not increased.

“We have a 50 % survival rate compared to the best product on the market. This is monumental in oncology,” says Bancel, highlighting the importance of this medical breakthrough.

K. Tovar

Source: Bancaynegocios

(Source image reference: Braňo, Unsplash)

Visit our news channel on Google News and follow us to get accurate, interesting information and stay up to date with everything. You can also see our daily content on Twitter and Instagram

La entrada Moderna hopes to offer new cancer vaccine in two years apareció primero en Bitfinance.